CClinicalTrials.gg
CompletedNCT06793176Updated Mar 5, 2025

Vibraimage Technology for Detecting Depression in Psychiatric Outpatients

An observational study in Depression, sponsored by Peking University People's Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Peking University People's Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
601
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Vibraimage technology captures high-frame-rate images of head-neck movements, converting them into vibraimages that display muscle vibration amplitude and frequency. Using algorithms and calculations, it derives an emotional index from these images. This non-contact, objective method analyzes psychological indicators through micro-movement detection. An algorithm has been developed to detect depression by calculating 12 emotional and 2 psychophysiological parameters. This diagnostic accuracy study aims to validate the technology's ability to diagnose depression in psychiatric outpatients.

02

Conditions studied

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 601 is above the median of 160 across 1,084 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 584 studies on the registry; 233 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Psychiatric outpatients attending the Beijing Huilongguan Hospital during the study period.

Inclusion criteria

  • Aged 18 to 70 years.
  • No difficulties in reading or writing Chinese; fluent in Mandarin.
  • Currently not taking psychotropic medications or on a stable dose for at least 6 weeks.
  • Provided informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Schizophrenia.
  • Bipolar disorder.
  • History of organic brain disease or significant head trauma.
  • Presence of severe systemic medical conditions.
  • Suicidal ideation or a score ≥3 on Item 3 ("Suicide") of the 17-item Hamilton Depression Rating Scale (HAMD-17).
  • Substance dependence or abuse.
  • Intellectual disability or dementia.
  • Inability to complete video capture or cooperate due to uncontrollable factors (e.g., hyperactivity, Parkinson's disease, or other conditions that prevent remaining still)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
601 participants (actual)
Patient registry
No

Groups and cohorts

  • Depressed Group

    This group consists of individuals who were ultimately diagnosed with depression by a specialist physician.

    Diagnostic Test: Video capture

  • Non-Depressed Group

    This group consists of individuals who were ultimately diagnosed as not having depression by a specialist physician.

    Diagnostic Test: Video capture

Interventions

  • Diagnostic testVideo capture

    A 20-second video capture of head-neck movements at high frame rates is conducted for all participants to obtain high-resolution images. The captured videos are analyzed using an algorithm based on Vibraimage technology to infer whether the participants have depression.

06

What researchers measure

Primary outcomes

  1. discrimination

    The primary outcome measure is the diagnostic discrimination of Vibraimage technology for depression, assessed by calculating the area under the receiver operating characteristic (ROC) curve. Participants first undergo video capture, followed by a clinical diagnosis of depression by a physician. Both the physician and participants are blinded to the results of the video analysis.

    Time frame: Participants undergo video capture and same-day clinical diagnosis by a physician. Video analysis and suggestive diagnosis are completed on the following day.

07

Study locations

1 site
  • Beijing HuiLongGuan Hospital
    Beijing, 100096, China
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data will be made available to qualified researchers upon reasonable request. Data sharing will be subject to approval by the principal investigator (PI) and the study sponsor.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06793176
Lead sponsor
Peking University People's Hospital
Collaborators
Beijing HuiLongGuan Hospital
Responsible party
Yi Feng, MD (Professor, Peking University People's Hospital) — Principal investigator
First posted
Jan 27, 2025
Start date
Jan 26, 2025
Primary completion
Mar 1, 2025
Completion
Mar 1, 2025
Last update
Mar 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion